S.Res. 545 — Agreed to in Senate

III 114th CONGRESS 2d Session S. RES. 545 IN THE SENATE OF THE UNITED STATES July 14, 2016 Ms. Stabenow submitted the following resolution; which was considered and agreed to RESOLUTION Supporting the designation of July 15, 2016, as Leiomyosarcoma Awareness Day. Whereas a soft tissue sarcoma is a rare type of cancer, accounting for approximately 1 percent of newly diagnosed cancers; Whereas Leiomyosarcoma (referred to in this preamble as LMS) is a malignant subtype of soft tissue sarcoma that originates in smooth muscle, often in the walls of blood vessels; Whereas LMS is highly aggressive and can be found throughout the body, but is especially concentrated in the uterus, abdominal cavity, and extremities; Whereas the National Institutes of Health classifies LMS as a rare disease; Whereas most oncologists will only see a few cases of LMS throughout a career; Whereas the causes of LMS are still unknown; Whereas LMS is largely resistant to standard chemotherapeutic agents, radiation treatment, and current immunotherapies; Whereas multidisciplinary care coordination teams, because of their expertise and experience, are critical to the health of LMS patients; Whereas LMS research will allow medical professionals to improve the quality of care for LMS patients, lead to better clinical outcomes, and promote longer survival for LMS patients; and Whereas increased education and awareness about LMS will contribute to the well-being of the communities of the United States: Now, therefore, be it That the Senate— (1) supports the designation of July 15, 2016, as Leiomyosarcoma Awareness Day; (2) recognizes the challenges faced by Leiomyosarcoma patients; and (3) commends the dedication of organizations, volunteers, researchers, and caregivers across the country working to improve the quality of life of Leiomyosarcoma patients and the families of Leiomyosarcoma patients.